Organigram Global (OGI) Common Equity (2018 - 2026)

Organigram Global (OGI) posted quarterly Common Equity of $673.9 million for Q1 2026, up 1.97% quarter-over-quarter from $660.9 million in Q4 2025.

Organigram Global (OGI) Common Equity (2018 - 2026) Analysis & Trends

Organigram Global (OGI) has reported Common Equity for 6 consecutive years, with $673.9 million the latest figure, recorded in Q1 2026.

In Q1 2026, Common Equity changed N/A year-over-year to $673.9 million; the TTM figure through Mar 2026 stood at $673.9 million (changed N/A YoY), while the FY2025 annual figure was $660.9 million, changed N/A from the prior year.
Common Equity advanced to $673.9 million in Q1 2026 per OGI's latest filing, from $660.9 million in the prior quarter.
Across five years, Common Equity topped out at $673.9 million in Q1 2026 and bottomed at $660.9 million in Q4 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Common Equity (Qtr)
1	Haleon	43.89 Bn	42.93 Bn	-	22.06 Bn
2	Teva Pharmaceutical Industries	43.01 Bn	39.35 Bn	2.15 Bn	7.76 Bn
3	Zoetis	31.52 Bn	29.84 Bn	1.05 Bn	3.15 Bn
4	Takeda Pharmaceutical	28.61 Bn	22.81 Bn	5.10 Bn	47.42 Bn
5	United Therapeutics	22.17 Bn	19.51 Bn	683.80 Mn	6.40 Bn
6	Viatris	18.73 Bn	17.85 Bn	1.46 Bn	14.26 Bn
7	Neurocrine Biosciences	15.51 Bn	15.12 Bn	935.80 Mn	3.69 Bn
8	Elanco Animal Health	11.75 Bn	11.22 Bn	798.00 Mn	6.59 Bn
9	Dr Reddys Laboratories	10.12 Bn	9.96 Bn	-	4.05 Bn
10	Organigram Global	151.29 Mn	151.17 Mn	28.97 Mn	673.92 Mn

Download Data